Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Xenon Pharmaceuticals Inc. (XENE)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 75,280,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product pipeline of neurology-focused therapies focus on epilepsy. Co.'s product candidates include: XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy and potentially other neurological disorders, such as major depressive disorder; and XEN496, a Kv7 potassium channel opener for the treatment of KCNQ2 developmental and epileptic encephalopathy. In addition, Co. has a license and collaboration agreement with Neurocrine Biosciences Inc. to develop NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of epilepsy.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 22,229 48,805 236,705 576,095
Total Sell Value $1,027,488 $2,098,369 $9,481,770 $22,449,223
Total People Sold 3 4 7 10
Total Sell Transactions 3 6 11 22
End Date 2024-02-01 2023-10-31 2023-05-02 2022-05-02

   
Records found: 231
  Page 3 of 10  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Pimstone Simon N. Director   –       •      –    2022-03-08 4/A S $30.80 $77,000 D/D (2,500) 193,135     -
   Pimstone Simon N. Director   –       •      –    2022-03-07 4 S $30.44 $948,260 D/D (31,086) 197,686     -
   Pimstone Simon N. Director   –       •      –    2022-03-07 4 D $30.23 $60,158 D/D (1,990) 228,772     -
   Pimstone Simon N. Director   –       •      –    2022-03-07 4 OE $3.67 $75,514 D/D 20,576 230,762     -
   Empfield James R. EVP, Drug Discovery   •       –      –    2022-03-07 4 S $30.54 $1,003,475 D/D (32,853) 10,000     -
   Empfield James R. EVP, Drug Discovery   •       –      –    2022-03-07 4 D $30.23 $291,629 D/D (9,647) 42,853     -
   Empfield James R. EVP, Drug Discovery   •       –      –    2022-03-07 4 OE $6.76 $291,400 D/D 42,500 51,805     -
   Pimstone Simon N. Director   –       •      –    2022-03-04 4 S $30.56 $285,425 D/D (9,325) 210,186     -
   Pimstone Simon N. Director   –       •      –    2022-03-04 4 D $31.42 $30,257 D/D (963) 219,511     -
   Pimstone Simon N. Director   –       •      –    2022-03-04 4 OE $3.67 $37,757 D/D 10,288 220,474     -
   Robin Sherrington EVP, Strategy & Innovation   •       –      –    2022-03-04 4 S $30.15 $662,208 D/D (21,710) 17,232     -
   Robin Sherrington EVP, Strategy & Innovation   •       –      –    2022-03-04 4 OE $3.67 $27,180 D/D 7,406 38,942     -
   Robin Sherrington EVP, Strategy & Innovation   •       –      –    2022-03-04 4 D $31.42 $21,868 D/D (696) 32,770     -
   Empfield James R. EVP, Drug Discovery   •       –      –    2022-03-04 4 S $30.79 $563,919 D/D (18,315) 10,000     -
   Empfield James R. EVP, Drug Discovery   •       –      –    2022-03-04 4 D $31.42 $210,043 D/D (6,685) 28,315     -
   Empfield James R. EVP, Drug Discovery   •       –      –    2022-03-04 4 OE $8.40 $210,000 D/D 25,000 35,000     -
   Kenney Christopher John Chief Medical Officer   •       –      –    2022-01-21 4 B $28.81 $20,167 D/D 700 700 2.74     -
   Azab Mohammad Director   –       •      –    2021-12-15 4 OE $3.67 $11,326 D/D 3,086 66,819     -
   Patou Gary Director   –       •      –    2021-12-08 4 OE $3.67 $7,549 D/D 2,057 25,630     -
   Von Seggern Christopher Chief Commercial Officer   •       –      –    2021-12-06 4 B $24.40 $97,600 D/D 4,000 4,000 2.74     -
   Robin Sherrington EVP, Strategy & Innovation   •       –      –    2021-05-28 4 S $18.81 $114,120 D/D (6,067) 32,232     -
   Robin Sherrington EVP, Strategy & Innovation   •       –      –    2021-05-28 4 D $18.91 $79,725 D/D (4,216) 38,299     -
   Robin Sherrington EVP, Strategy & Innovation   •       –      –    2021-05-28 4 OE $3.76 $97,907 D/D 25,719 40,491     -
   Holler Frank A Director   –       •      –    2021-05-27 4 S $18.68 $206,701 D/D (11,064) 143,653     -
   Holler Frank A Director   –       •      –    2021-05-27 4 D $18.88 $121,172 D/D (6,418) 154,717     -
  231 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 3 of 10
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us